These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30806186)

  • 1. Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?
    Turker P; Segersten U; Malmström PU; Hemdan T
    Scand J Urol; 2019 Feb; 53(1):45-50. PubMed ID: 30806186
    [No Abstract]   [Full Text] [Related]  

  • 2. Bcl-2 predicts response to neoadjuvant chemotherapy and is overexpressed in lymph node metastases of urothelial cancer of the bladder.
    Kiss B; Skuginna V; Fleischmann A; Bell RH; Collins C; Thalmann GN; Seiler R
    Urol Oncol; 2015 Apr; 33(4):166.e1-8. PubMed ID: 25596645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
    Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
    Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
    Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours.
    Sengeløv L; von der Maase H; Lundbeck F; Barlebo H; Colstrup H; Engelholm SA; Krarup T; Madsen EL; Meyhoff HH; Mommsen S; Nielsen OS; Pedersen D; Steven K; Sørensen B
    Acta Oncol; 2002; 41(5):447-56. PubMed ID: 12442921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choline-phosphate cytidylyltransferase-α as a possible predictor of survival and response to cisplatin neoadjuvant chemotherapy in urothelial cancer of the bladder.
    Hemdan T; Turker P; Malmström PU; Segersten U
    Scand J Urol; 2018 Jun; 52(3):200-205. PubMed ID: 29475387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
    Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
    Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of neoadjuvant chemotherapy for the patients with locally invasive bladder cancer].
    Noguchi S; Takase K; Yoshida M; Yumura Y; Yamashita Y; Oogo Y; Miyoshi Y
    Nihon Hinyokika Gakkai Zasshi; 2005 Jul; 96(5):548-53. PubMed ID: 16083032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of biomarkers for neoadjuvant systemic chemotherapy before cystectomy in patients with urinary bladder cancer.
    Türker P; Wernroth ML; Malmström PU; Segersten U; Hemdan T
    Transl Res; 2021 Sep; 235():77-84. PubMed ID: 33766713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy.
    Zareba P; Patterson L; Pandya R; Margel D; Hotte SJ; Mukherjee SD; Elavathil L; Daya D; Shayegan B; Pinthus JH
    Urol Oncol; 2014 Oct; 32(7):975-80. PubMed ID: 25027682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
    Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
    Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D2-40/podoplanin expression in cancer stroma by immunohistochemical staining is associated with poor prognosis in bladder cancer patients after radical cystectomy.
    Okajima E; Tomizawa M; Shimada K; Negishi T; Nishiyama N; Kitamura H
    Urol Oncol; 2020 Oct; 38(10):797.e7-797.e13. PubMed ID: 32576528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
    Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
    Wolf HK; Stöber C; Hohenfellner R; Leissner J
    Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.
    Zargar-Shoshtari K; Zargar H; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
    J Urol; 2016 Jan; 195(1):53-9. PubMed ID: 26205531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single-arm Phase II Trial of Neoadjuvant Cabazitaxel and Cisplatin Chemotherapy for Muscle-Invasive Transitional Cell Carcinoma of the Urinary Bladder.
    Challapalli A; Masson S; White P; Dailami N; Pearson S; Rowe E; Koupparis A; Oxley J; Abdelaziz A; Ash-Miles J; Bravo A; Foulstone E; Perks C; Holly J; Persad R; Bahl A
    Clin Genitourin Cancer; 2021 Aug; 19(4):325-332. PubMed ID: 33727028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy.
    Cooke PW; James ND; Ganesan R; Burton A; Young LS; Wallace DM
    BJU Int; 2000 May; 85(7):829-35. PubMed ID: 10792161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.
    Zargar-Shoshtari K; Sverrisson EF; Sharma P; Gupta S; Poch MA; Pow-Sang JM; Spiess PE; Sexton WJ
    Clin Genitourin Cancer; 2016 Feb; 14(1):82-8. PubMed ID: 26411593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.